Population-level data can help medical practitioners use electronic health records to identify patients at risk for cardiovascular disease.
Patients using a high-intensity statin after a STEMI experienced a significant increase in minimum fibrous cap thickness.
For alirocumab to be considered cost-effective compared with generic ezetimibe, its annual price would have to be reduced to less than $90.
Smoking, hypertension, and diabetes contributed to more than a quarter of excess CVD risk in individuals with heterozygous familiar hypercholesterolemia.
Ultrasonography or MRI may improve diagnosis of ATX in familial hypercholesterolemia, identifying patients at risk for more severe coronary artery disease.
Despite the frequency with which it occurs, familial hypercholesterolemia often goes undiagnosed, with only 10% of affected patients aware of this genetic disorder.
Hypercholesterolemic patients who tolerate only lowest-dose statin or non-statin lipid lowering therapy can achieve LDL-C reduction with alirocumab.
Adherent patients receiving high-intensity statin and/or ezetimibe therapy have the lowest cardiovascular risk.
Metabolic syndrome and psoriatic arthritis were highly prevalent comorbidities in patients with plaque psoriasis.
Ezetimibe combined with statin therapy showed modest or moderate benefits in reducing major CVD event risk.
The data showed a <0.1% risk of statin-induced muscle injury, including rhabdomyolysis, and a ~0.001% risk of serious hepatotoxicity. Statin-induced newly diagnosed diabetes mellitus was a ~0.2% risk per year of treatment, depending on baseline risk in the patients studied.
Statin use is associated with better cortical bone characteristics in older women with osteoporosis, but results are dependent upon the potency of the statins.
Socioeconomically challenged patients with obesity and elevated cardiovascular risk may benefit from digital obesity treatment combined with health system resources.
The addition of ezetimibe to simvastatin reduced ischemic risk compared with placebo, with consistent relative risk reductions in patients with and without polyvascular disease.
Researcher observed a much lower rate of discontinuations due to skeletal muscle events with alirocumab in the open-label extension trial compared with the double-blind parent study (3.2% vs 15.9%).
In patients with primary hypercholesterolemia, short-term treatment with simvastatin improved the lipid profile and exerted a beneficial effect on a wide range of proatherogenic and prothrombotic parameters.
A healthy lifestyle for lowering cholesterol should be emphasized for reducing cardiovascular risk across the life course.
Evolocumab consistently reduced LDL-C with no increase in adverse events over a 5-year study period.
First-year nonadherence and discontinuation are high among older adults prescribed statins.
The data showed MAEs onset was significantly faster with atorvastatin and rosuvastatin compared with simvastatin; a comparison with other statins could not be established due to the small number of cases identified.
Early detection of lipidome characteristics could help identify the early onset of type 2 diabetes.
There is a lack of convincing evidence for an association between statin use and noncardiovascular disease outcomes.
Statin therapy is associated with reduced mitochondrial complex II-linked respiration, and statin-induced myalgia is coupled to an increased intrinsic mitochondrial respiratory function, while intramuscular [coenzyme Q10] levels are unaltered.
Investigators analyze characteristics of participants with acquired partial lipodystrophy who developed severe metabolic abnormalities.
Genetic testing should become the standard of care for patients with definite or probable familial hypercholesterolemia.
A variety of underlying mechanisms may be attributed to the role of statins in preventing bone-related disorders.
Low-density lipoprotein cholesterol (LDL-C) and non-high density lipoprotein cholesterol (non-HDL-C) ≥160 mg/dL are independently associated with increased relative risk of cardiovascular disease (CVD) mortality in a low-risk cohort.
"We are extremely disappointed with the FDA's decision. We continue to feel strongly that Waylivra demonstrates a favorable benefit/risk profile in people with FCS," said Akcea CEO, Paula Soteropoulos.
Serum 25-hydroxyvitamin D [25(OH)D] is independently and inversely associated with total cholesterol, low-density lipoprotein (LDL) cholesterol, and high-density lipoprotein (HDL) cholesterol in children.
Nutraceuticals may offer a solution to patients who cannot tolerate statins because of severe muscle pain.
Endocrinology Advisor Articles
- Testosterone Use Remains High Among Men With Coronary Artery Disease
- Insulin Analogs vs Regular Human Insulin for Type 2 Diabetes
- Primary Characteristics of PCOS Predictive of Obstetric Complications
- Trends in Bisphosphonate Use and Hip Fracture Rates in Denmark
- Maternal Thyroid Function in Pregnancy Linked to Childhood Risk for Disease
- ADA's 2019 Standards of Medical Care in Diabetes Focus on Patient-Centered Care
- Sleep Habits Affect Insulin Sensitivity in Adolescents With Overweight, Obesity
- Levothyroxine Associated With Increased Mortality in Patients With Heart Failure
- Head-to-Head Comparison of Professional vs Personal CGM Systems in T1D
- Dual vs Triple Therapy for Metformin Treatment Intensification in Type 2 Diabetes
- Risk for Congenital Heart Defects in Offspring of Mothers With Obesity
- Is the MiniMed 670G System Safe for Children With Type 1 Diabetes?
- Gender-Affirming Hormonal Treatment and Long-Term Bone Safety
- Obesity Linked to Lower Gray Matter Brain Volume
- No Evidence for Health Benefits of Nonsugar Sweeteners